Edition:
United Kingdom

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

57.71USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$57.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,590
52-wk High
$68.57
52-wk Low
$41.64

Chart for

About

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by... (more)

Overall

Beta: 1.49
Market Cap(Mil.): $872.76
Shares Outstanding(Mil.): 14.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Anika Q4 Earnings Per Share $0.53

* ANIKA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

21 Feb 2018

BRIEF-Anika Therapeutics Announces Strategic Collaboration With The Institute Of Integrative Biology

* ANIKA THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH THE INSTITUTE OF INTEGRATIVE BIOLOGY AT THE UNIVERSITY OF LIVERPOOL TO DEVELOP AN INNOVATIVE THERAPY FOR OSTEOARTHRITIS Source text for Eikon: Further company coverage:

01 Feb 2018

BRIEF-Anika Therapeutics Expands Strategic Collaboration With Institute For Applied Life Sciences

* ANIKA THERAPEUTICS EXPANDS STRATEGIC COLLABORATION WITH THE INSTITUTE FOR APPLIED LIFE SCIENCES (IALS) AT THE UNIVERSITY OF MASSACHUSETTS AMHERST TO DEVELOP INNOVATIVE THERAPY FOR RHEUMATOID ARTHRITIS Source text for Eikon: Further company coverage:

24 Jan 2018

BRIEF-Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment

* ANIKA ANNOUNCES FDA 510(K) CLEARANCE FOR ITS INJECTABLE HA-BASED BONE REPAIR TREATMENT

27 Dec 2017

BRIEF-Anika reports Q3 earnings per share $0.46

* Q3 revenue rose 5 percent to $27.2 million Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Anika completes enrollment in second pivotal phase III trial of cingal

* Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis

25 Oct 2017

BRIEF-Anika announces forthcoming appointment of Thomas Finnerty as chief human resources officer

* Anika announces the forthcoming appointment of Thomas M. Finnerty as chief human resources officer Source text for Eikon: Further company coverage:

23 Oct 2017

BRIEF-Anika Therapeutics announces regulatory approval for Monovisc® in Australia

* Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints

16 Oct 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $129.91 0.00
Novartis AG (NOVN.S) CHF79.60 -0.38
Pfizer Inc. (PFE.N) $35.74 -0.02
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
Merck & Co., Inc. (MRK.N) $54.57 +0.02
Bayer AG (BAYGn.DE) €98.02 -0.42
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.79 -0.10
Abbott Laboratories (ABT.N) $58.99 0.00

Earnings vs. Estimates